Cabometyx (cabozantinib)
pCPA File Number:
21238
Negotiation Status:
Concluded with an LOI
Indication(s):
Hepatocellular Carcinoma (HCC) in adults after prior therapy
Sponsor/Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
CDA-AMC Project Number:
PC0186-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: